Skip to Content
MilliporeSigma
All Photos(1)

Key Documents

344597

Sigma-Aldrich

FTY720

Sign Into View Organizational & Contract Pricing


About This Item

UNSPSC Code:
12352200
NACRES:
NA.51

Pricing and availability is not currently available.

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Matthew J Caicco et al.
Journal of controlled release : official journal of the Controlled Release Society, 166(3), 197-202 (2013-01-12)
Stimulation of endogenous neural stem/progenitor cells (NSPCs) with therapeutic factors holds potential for the treatment of stroke. Cyclosporin A (CsA) is a particularly promising candidate molecule because it has been shown to act as a survival factor for these cells
Maryam Zadeh-Khorasani et al.
Journal of translational medicine, 11, 4-4 (2013-01-09)
Animal models of human inflammatory diseases have limited predictive quality for human clinical trials for various reasons including species specific activation mechanisms and the immunological background of the animals which markedly differs from the genetically heterogeneous and often aged patient
Andrea J Mothe et al.
Biomaterials, 34(15), 3775-3783 (2013-03-08)
Traumatic injury to the spinal cord causes cell death, demyelination, axonal degeneration, and cavitation resulting in functional motor and sensory loss. Stem cell therapy is a promising approach for spinal cord injury (SCI); however, this strategy is currently limited by
Eyal Zur
International journal of pharmaceutical compounding, 17(1), 10-22 (2013-05-01)
Compounding pharmacists throughout the world are compounding a special type of capsule called "slow-release." This type of capsule is a compounding pharmacy application of the commercial hydrophilic matrix tablets. It is a relatively simple system that allows formulating a robust
Navnit Shah et al.
Journal of pharmaceutical sciences, 102(3), 967-981 (2013-01-03)
The present work deals with improving the solubility of vemurafenib, a practically insoluble drug, by converting it into an amorphous-solid dispersion using a solvent-controlled precipitation process. The dispersion containing vemurafenib and hypromellose acetate succinate (HPMCAS), an enteric polymer, is termed

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service